

AVANIR PHARMACEUTICALS

Form 8-K

August 25, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 24, 2004**

**Avanir Pharmaceuticals**

(Exact name of registrant as specified in its charter)

**001-15803**

(Commission File Number)

**California**

(State or other jurisdiction of  
incorporation)

**33-0314804**

(I.R.S. Employer Identification  
No.)

**11388 Sorrento Valley Road, San Diego, California 92121**

(Address of principal executive offices, with zip code)

**(858) 622-5200**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01 Other Events**

On August 24, 2004, Avanir Pharmaceuticals issued a press release announcing the results of a pivotal Phase III clinical trial evaluating the safety and effectiveness of Neurodex in the treatment of pseudobulbar affect in patients with multiple sclerosis. A copy of this press release is filed herewith as Exhibit 99.1.

Also on August 24, 2004, Avanir hosted a publicly available conference call discussing the results of this clinical trial. A replay of this conference call will be available online at [www.avanir.com](http://www.avanir.com) through November 22, 2004, and by telephone through August 31, 2004, by dialing 888-266-2081 (domestic) and 703-925-2533 (international) and entering the passcode 546536.

**Item 9.01 Financial Statements and Exhibits**

Exhibit

99.1 Press release, dated August 24, 2004

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Avanir Pharmaceuticals**

Date: August 24, 2004

By: /s/ Gregory P. Hanson  
Gregory P. Hanson, CMA  
Chief Financial Officer

-3-